Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Drugs
Published in: Pediatric Drugs 2/2005

01-03-2005 | Original Research Article

Economic Evaluation of an Extended Acellular Pertussis Vaccine Program for Adolescents in Québec, Canada

Authors: Michael Iskedjian, John H. Walker, Gaston De Serres, Thomas R. Einarson

Published in: Pediatric Drugs | Issue 2/2005

Login to get access

Abstract

Objective: Pertussis is a frequent cause of cough illness in adolescents. In Canada, immunization against pertussis in public programs has been restricted to children under 7 years of age. The purpose of this analysis was to estimate the health and economic impact of an additional booster dose of the acellular vaccine in adolescents in Québec.
Method: We performed a cost-effectiveness analysis, based on a predictive spreadsheet dynamic model following a cohort of 90 929 adolescents in Québec from the age of 14 years over a 10-year period from the Québec Ministry of Health (MOH) and societal (SOC) perspectives. The model was used to compare costs (2003 values) and benefits of an adolescent vaccination program (AVP), including a diptheria, tetanus, and acellular pertussis (dTacp) vaccine administered at age 14 years, with current practice.
Results: From the MOH perspective, a booster vaccination of dTacp at age 14 years via the AVP would produce a yearly additional expected cost of $Can1.06 per adolescent with an incremental cost-effectiveness ratio (ICER) of $Can480 per pertussis case avoided based on a 10-year period. When outcomes are discounted at 3%, the ICER rises to $Can527 per discounted pertussis case avoided. From the SOC perspective, the AVP would cost $Can0.83 per adolescent per year with an additional cost per avoided pertussis case of $Can377 ($Can414 per additional discounted case of pertussis avoided). Over the 10-year period, 2012 non-discounted cases of pertussis would be prevented with approximately two hospital admissions averted.
Conclusion: This study suggests that administering a booster dose of dTacp at age 14 years to replace the diptheria and tetanus vaccination will slightly increase the economic burden from MOH and SOC perspectives; however, the number of pertussis cases and the number of hospital admissions will decrease.
Footnotes
1
The use of trade names is for product identification purposes only and does not imply endorsement.
 
Literature
1.
Aoyama T, Takeuchi Y, Goto A, et al. Pertussis in adults. Am J Dis Child 1992; 146: 163–6PubMed
2.
3.
Orenstein W. Pertussis in adults: epidemiology, signs, symptoms, and implication for vaccination. Clin Infect Dis 1999; 28: S147–50PubMedCrossRef
4.
Gardner P. Indications for acellular pertussis vaccines in adults: the case for selective, rather than universal, recommendations. Clin Infect Dis 1999; 28: S131–5PubMedCrossRef
5.
6.
Health Canada. Canadian communicable disease report: statement on adult/adolescent formulation of combined acellular pertussis, tetanus, and diptheria vaccine. Ottawa (ON): Health Canada, 2000: 8
7.
De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000; 182: 174–9PubMedCrossRef
8.
Nennig M. Prevalence and incidence of adult pertussis in an urban population. JAMA 1996; 275: 1672–4PubMedCrossRef
9.
10.
Deville JG. Frequency of unrecognized Bordetella pertussis infections in adults. Clin Infect Dis 1995; 21: 639–42PubMedCrossRef
11.
Halperin S. Persistence of pertussis in an immunized population: results of the Nova Scotia enhanced pertussis surveillance program. J Pediatr 1989; 115: 689–93
12.
De Serres G. Pertussis in Quebec: ongoing epidemic since the late 1980s. Can Commun Dis Rep 1995; 21: 45–7PubMed
13.
Bentsi-Enchill A, Halperin S, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997; 15: 301–6PubMedCrossRef
14.
Health Canada. Canada communicable disease report: pertussis in children hospitalized at five Canadian pediatric tertiary care centres. Ottawa (ON): Health Canada, 1994: 20, 31–4
15.
Keitel W, Edwards K. Pertussis in adolescents and adults: time to reimmunize? Semin Respir Infect 1995; 10: 51–7PubMed
16.
Tam T, Bentsi-Enchill A. The return of the 100-day cough: resurgence of pertussis in the 1990s. CMAJ 1998; 159: 695–6PubMed
17.
18.
Halperin S, Wang E, Law B. Epidemiological features of pertussis in hospitalized patients in Canada, 1991–1997: report of the Immunization Monitoring Program-Active (IMPACT). Clin Infect Dis 1999; 28: 1238–43PubMedCrossRef
19.
Cherry J, Baraff L, Hewlett E. The past, present and future of pertussis: the role of adults in epidemiology and future control. West J Med 1989; 150: 319–28PubMed
20.
Health Canada. Canada communicable disease report: prevention of pertussis in adolescents and adults. Ottawa (ON): Health Canada, 2003: 29 (ACS-5,6) (DCC-5,6), 1–9
21.
22.
Keitel W, Muenz L, Decker M, et al. A randomized clinical trial of acellular pertussis vaccines in health adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 1999; 180: 397–403PubMedCrossRef
23.
Ward J, Partridge S, Chang S, et al. Acellular pertussis vaccine efficacy and epidemiology of pertussis in adolescents and adults: NIH multicenter adult pertussis trial (APERT). DHHD/NIH, National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases. Acellular Pertussis Vaccine Conference; 2000 Nov 12–14; Bethesda
24.
Tran Minh N, Qiushui H, Ramalho A, et al. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents. Pediatrics 2004; 104: e70–6CrossRef
25.
Iskedjian M, Walker J, Hemels M. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada. Vaccine 2004; 22: 4215–27PubMedCrossRef
26.
StatCan. Neighbourhood income and demographics, taxfilers and dependents, by sex and single years of age, annual (number) [table 111—0006] [online]. Available from URL: http://​cansim2.​statcan.​ca [Accessed 2004 Feb 26]
27.
StatCan. Mortality: summary list of causes, 1999. Catalogue no. 84F0209XPB, 1–192. Ottawa (ON): Statistics Canada, 2002
28.
StatCan. Profile of the Canadian population by age and sex: Canada ages. Catalogue no. 96F0030XIE2001002, 3–28. Ottawa (ON): Statistics Canada, 2002
29.
30.
31.
Manga P, Scott J, Chung P. A benefit cost analysis of changing to an acellular vaccine for pertussis in Canada. Ottawa (ON): Pran Manga and Associates, 1997
32.
Ntezaybo B, De Serres G, Duval B. Pertussis resurgence in Canada largely caused by a cohort effect. Pediatr Infect Dis J 2003; 22: 22–7CrossRef
33.
Gustafsson L, Hallander H, Olin P, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996; 334: 349–55PubMedCrossRef
34.
Li J, Taylor B. Childhood immunisation and family size. Health Trends 1993; 25: 16–9PubMed
35.
De Serres G, Boulianne N, Duval B, et al. Effectiveness of a whole cell pertussis vaccine in child-care centres and schools. Pediatr Infect Dis 1996; 15: 519–24CrossRef
36.
Coalition for the Canadian Immunization Awareness Program. The Canadian Coalition for Influenza Immunization: the value of immunization in the future of Canada’s health system. Ottawa (ON): Canadian Public Heath Association, 2001
37.
Jacobs P, Assiff L, Bachynsky J, et al. A national list of provincial costs for health care: Canada 1997/8. Edmonton (AB): Institute for Health Economics, 2000
38.
Sadoway D, Plain R, Soskolne C. Infant and preschool immunization delivery in Alberta and Ontario: a partial cost-minimization analysis. Can J Public Health 1990; 81: 146–51PubMed
39.
Centres for Disease Control and Prevention. Pertussis. In: Atkinson W, Wolfe C, editors. Epidemiology and prevention of vaccine-preventable diseases. 7th ed. The Pink Book. Washington (WA): United States Department of Health and Human Services, 2003: 58–70
40.
Ross D. Contact tracing for pertussis [letter]. CMAJ 1999; 160: 786PubMed
41.
42.
43.
Québec Ministry of Health and Social Services. Québec manuel des medicins omnipracticiens 2001. Québec City (QC): Québec Ministry of Health and Social Services, 2002
44.
Ministry of Health. Schedule of Benefits: Physician Services Under the Health Insurance Act (April 1, 2001). Ottawa (ON): Ministry of Health, 2001
45.
Québec Ministry of Health and Social Services. Québec liste des medicaments 2002. Québec City (QC): Québec Ministry of Health and Social Services, 2002
46.
Laurichesse H, Robin F, Gerbaud L, et al. Empirical therapy for nonhospitalized patients with community-acquired pneumonia: study group of general practitioners. Eur J Respir Dis 1998; 11: 73–8CrossRef
47.
Ferrand P, Mercier C, Jankowski R, et al. Acute sinusitus in adults: management by general practitioners. Presse Med 2001; 30: 1049–54PubMed
48.
Ontario Case Costing Project. Average pediatric nursing costs for Bordetella pertussis. Toronto (ON): Ontario Case Costing Project, 2002
49.
StatCan. Consumer price index: health care. CANSIM II -v735519 Table 326–0001. Ottawa (ON): Statistics Canada, 2003
50.
StatCan. Employment earnings and hours. Catalogue no. 72-002-XIB — February, 2003, x-xi. Ottawa (ON): Statistics Canada, 2003
51.
Québec Ministry of Health and Social Services. Quebec manuel des medicins specialistes 2001. Québec City (QC): Québec Ministry of Health and Social Services, 2002
52.
53.
54.
Baron S, Njamkepo E, Grimprel E, et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis 1998; 17: 412–8CrossRef
55.
Iskedjian M, Einarson T, O’Brien B, et al. Economic evaluation of a new acellular vaccine for pertussis in Canada. Pharmacoeconomics 2001; 19: 551–63PubMedCrossRef
56.
Deeks S, De Serres G, Boulianne N. Failure of physicians to consider the diagnosis in children with pertussis. Clin Infect Dis 1999; 28: 840–6PubMedCrossRef
57.
Mast E, Berg J, Hanrahan L, et al. Risk factors for measles in a previously vaccinated population and cost-effectiveness of revaccination strategies. JAMA 1990; 264: 2529–33PubMedCrossRef
58.
Purdy K, Hay J, Botteman M, et al. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 2004; 39: 20–8PubMedCrossRef
Metadata
Title
Economic Evaluation of an Extended Acellular Pertussis Vaccine Program for Adolescents in Québec, Canada
Authors
Michael Iskedjian
John H. Walker
Gaston De Serres
Thomas R. Einarson
Publication date
01-03-2005
Publisher
Springer International Publishing
Published in
Pediatric Drugs / Issue 2/2005
Print ISSN: 1174-5878
Electronic ISSN: 1179-2019
DOI
https://doi.org/10.2165/00148581-200507020-00005

Other articles of this Issue 2/2005

Pediatric Drugs 2/2005 Go to the issue

Leading Article

Anthracycline-Induced Cardiotoxicity in Children with Cancer

Therapy In Practice

Neonatal Chlamydial Infections

Therapy In Practice

Staphylococcal Skin Infections in Children

Review Article

Use of Probiotics in Children with Acute Diarrhea